ライフサイエンスコーパス: leukocyte antigen

1 atibility complex (MHC) class I genes (human leukocyte antigen A [HLA-A], -B, and -C genes) may affec

2 Y)-box 30 activated naive T cells from human leukocyte antigen A*02:01-positive human donors.

3 ll patients' results were positive for human leukocyte antigen-A29.

4 No donor-specific human leukocyte antigen Abs or rejection episodes were noted,

5 tudies have revealed associations with human leukocyte antigen and non-human leukocyte antigen genes

6 tion between HIV genetic variation and human leukocyte antigen and the other studying host range dist

7 art technology employed to assess anti-human leukocyte antigen antibodies (Anti-HLA Ab) for donor-rec

8 de novo detection of circulating anti-human leukocyte antigen antibodies, and clinically significant

9 e, human leukocyte antigen mismatches, human leukocyte antigen antibodies, cold ischemia time, living

10 caid Services to evaluate whether anti-human leukocyte antigen antibodies, measured as panel reactive

11 use of everolimus, and available anti-human leukocyte antigen antibody data.

12 th HIV/Mtb had decreased expression of human leukocyte antigen antigen D related and the costimulator

13 e production and significantly reduced human leukocyte antigen - antigen D related expression.

14 onse to bacterial stimulation and less human leukocyte antigen - antigen D related.

15 eripheral blood mononuclear cells, and human leukocyte antigen-antigen D related expression on circul

16 sis of DHRs with the identification of human leukocyte antigens as predisposing factors.

17 -cell infiltrates and a strong genetic human leukocyte antigen association represent characteristic f

18 Human leukocyte antigen-B27 (HLA-B27)-positive acute anterior

19 Human leukocyte antigen-B40 group and HLA-B8 were identified a

20 ng the highly sensitive single-antigen human leukocyte antigen bead assay 5.1 +/- 3.9 months after th

21 rategy relies on initial prediction of human leukocyte antigen-binding peptides by in silico algorith

22 owever, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell receptor fro

23 The leukocyte antigen CD69 modulates the setting and progres

24 nts, we observed reduced expression of human leukocyte antigen class DR (HLA-DR) and proinflammatory

25 Human leukocyte antigen class I (HLA)-restricted CD8(+) T lymp

26 years, adjusted P = 0.010) and several human leukocyte antigen class I (HLA-I) alleles, including HLA

27 al diversity of the highly polymorphic human leukocyte antigen class I (HLA-I) genes underlies succes

28 Human leukocyte antigen class I (HLA-I) molecules are encoded

29 ient presentation of tumor antigens by human leukocyte antigen class I (HLA-I) molecules.

30 lin-like receptors (KIRs) that bind to human leukocyte antigen class I (HLA-I).

31 ng placental trophoblast cells express human leukocyte antigen class I ligands (HLA-E, HLA-G, and HLA

32 lysis of immune responses ex vivo used human leukocyte antigen class I pentamers, intracellular cytok

33 cytometry with ultrasensitive peptide-human leukocyte antigen class I tetramer staining to quantify

34 between the T-cell receptor (TCR) and human leukocyte antigen class II (HLA-II).

35 and c-Met and the immunologic markers human leukocyte antigen class II and programmed death ligand 1

36 ory of type 1 diabetes and susceptible human leukocyte antigen class II genotypes.

37 the antigens that will be presented by human leukocyte antigen class II molecules (HLA-II), hindering

38 em through their interactions with the human leukocyte antigen complex, and neoantigen presence has r

39 r support the link between ASD and the human leukocyte antigen complex.

40 xt of human leukocyte antigen (peptide-human leukocyte antigen complex; pHLA) molecules on tumor cell

41 Tumor-associated peptide-human leukocyte antigen complexes (pHLAs) represent the larges

42 of circulating activated CD4+ T cells (human leukocyte antigen-D related [HLA-DR]+CD38+CD4+) (from 3.

43 monocytes expressed reduced levels of human leukocyte antigen-D-related peptide and released less so

44 Monocyte expression of human leukocyte antigen-D-related peptide, sol-tumor necrosis

45 ompared to non-PSC controls, including human leukocyte antigen DM alpha chain and chemokine (C-C moti

46 Human leukocyte antigen-DM (HLA-DM) is an integral component o

47 Anti-human leukocyte antigen donor-specific antibodies (DSAs), espe

48 dyslipidemia (P=0.009), class II anti-human leukocyte antigen donor-specific antibodies (P=0.004), a

49 ompatibility complex class II (MHC-II) human leukocyte antigen DR isotype (HLA-DR) is an essential en

50 n 38 (CD38) and CD69 but low levels of human leukocyte antigen DR, CD80, and CD86 at baseline.

51 evels of macrophage-derived chemokine, human leukocyte antigen DR, CD80, and CD86 were increased in a

52 egulated macrophage-derived chemokine, human leukocyte antigen DR, CD86, and CD80 correlated positive

53 atory T-cell frequency, activated CD38+Human Leukocyte Antigen - DR isotype (HLA-DR)+ CD4 and CD8 T c

54 showed increased circulating activated human leukocyte antigen, DR isotype ([HLA-DR] positive) CD8(+)

55 ultured in perioperative serum and CD14Human Leukocyte Antigen-DR (HLA-DR) [monocyte HLA-DR (mHLA-DR)

56 he ocular surface inflammatory markers human leukocyte antigen-DR (HLA-DR) and intercellular adhesion

57 both demonstrated increased levels of human leukocyte antigen-DR (HLA-DR) following IFN-gamma stimul

58 oses, an apparent increase in monocyte human leukocyte antigen-DR expression (> 5,000 monoclonal anti

59 septic shock patients stratified using human leukocyte antigen-DR expression on monocytes (mHLA-DR).

60 gadolinium 160 ((160)Gd)-labeled anti-human leukocyte antigen-DR isotope (HLA-DR) antibodies to dete

61 cluded receptor occupancy and monocyte human leukocyte antigen-DR levels.

62 We found a profound decrease in human leukocyte antigen-DR on Mo and DCs in burned patients wi

63 The expression of human leukocyte antigen-DR was determined on all DCs and Mo, a

64 lass II (MHC II) and instead expresses human leukocyte antigen DR1 (HLA-DR1).

65 zed in SARS-CoV- and MERS-CoV-infected human leukocyte antigen DR2 and DR3 transgenic mice, indicatin

66 class II antigen was replaced with the human leukocyte antigen DR4 (HLA-DR4).

67 id, which suppresses the expression of human leukocyte antigen E (HLA-E) in cancer cells, thus activa

68 lity complex (MHC), a mouse homolog of human leukocyte antigen-E (HLA-E), inhibits antibody-mediated

69 PPCLs uniformly expressed class I human leukocyte antigen, epithelial cell adhesion molecule, an

70 sidedness dependent differential hMSC human leukocyte antigen expression, angiogenic and inflammator

71 d T cells and frequently downregulated human leukocyte antigen expression.

72 tibility complex (MHC) molecule HLA-F (human leukocyte antigen F) regulates the immune system in preg

73 indoleamine 2,3 dioxygenase (IDO), and human leukocyte antigen G (HLA-G) was determined.

74 Human leukocyte antigen G (HLA-G), a nonclassic HLA class Ib m

75 immune tolerance mechanism induced by human leukocyte antigen G (HLA-G), was investigated.

76 une tolerance mechanism induced by the human leukocyte antigen G (HLA-G).

77 mber of the KIR family that recognizes human leukocyte antigen G and mediates NK-cell activation thro

78 Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression

79 differentiation preferentially toward human leukocyte antigen-G(+) pcEVT, and that an intact HIF com

80 eptor(+) villous cytotrophoblasts into human leukocyte antigen-G(+) proximal column EVT (pcEVT) and i

81 Invading human leukocyte antigen-G+ (HLA-G+) extravillous trophoblasts

82 kin-10 gene (IL10) T3575A), rs6457327 (human leukocyte antigen gene (HLA) class I), rs10484561 (HLA c

83 r, the functional relationship between human leukocyte antigen gene(s) and disease development remain

84 ts associated with DHRs are located in human leukocyte antigen genes and genes involved in drug metab

85 Several of the human leukocyte antigen genes at this locus, such as HLA-A, HL

86 s with human leukocyte antigen and non-human leukocyte antigen genes of 3 major histocompatibility co

87 zed for disease-associated variants in human leukocyte antigen genes; results must be carefully inter

88 he child after adjustment for country, human leukocyte antigen genotype, family history of celiac dis

89 raves' disease controls), using direct human leukocyte antigen genotyping and SNP-based genome-wide a

90 resent review describes the biology of human leukocyte antigen haplotype mismatched ("haploidentical"

91 preparing the cells from donors whose human leukocyte antigen-haplotype are homozygous.

92 The HLA-DRB1*01 allele of the human leukocyte antigen has been associated with acute coronar

93 L (ALY) is presented in the context of human leukocyte antigen HLA-A*02:01 molecules for recognition

94 The immunosuppressive human leukocyte antigens HLA-G and HLA-F are expressed on trop

95 isk stage III melanoma were grouped by human leukocyte antigen (HLA) -A2 status.

96 nalyzed humoral immune responses to nonhuman leukocyte antigen (HLA) after cardiac transplantation to

97 der strong genetic control by class II human leukocyte antigen (HLA) allele combinations.

98 MHC (chr6: 29.6-33.1 Mb), imputing 216 human leukocyte antigen (HLA) alleles and 4 complement compone

99 ies new associations between classical human leukocyte antigen (HLA) alleles and common immune-mediat

100 searched for genetic associations with human leukocyte antigen (HLA) alleles and IFN-lambda3 gene (IF

101 Specific human leukocyte antigen (HLA) alleles have been identified in

102 e detected the involvement of the same human leukocyte antigen (HLA) alleles in both SCZ and MS, but

103 de Polymorphisms (SNPs) and 38 imputed Human Leukocyte Antigen (HLA) alleles were analyzed through a

104 ct of source partner HIV-1 RNA levels, human leukocyte antigen (HLA) alleles, and innate responses th

105 wide association study (GWAS), imputed human leukocyte antigen (HLA) alleles, exome array and copy-nu

106 disease, is associated with particular human leukocyte antigen (HLA) alleles.

107 a variety of tissues, cell types, and human leukocyte antigen (HLA) alleles.

108 We performed human leukocyte antigen (HLA) analysis in 25 nontumor anti-LGI

109 edically important regions such as the human leukocyte antigen (HLA) and killer cell immunoglobulin-l

110 De novo donor-specific human leukocyte antigen (HLA) antibodies (DSA) posttransplant

111 lications including the development of human leukocyte antigen (HLA) antibodies.

112 idney recipients monitored for de novo human leukocyte antigen (HLA) antibody (Ab) occurrence to gain

113 d single allele cells to identify anti-human leukocyte antigen (HLA) antibody cross-species reactivit

114 e to determine the titer of individual human leukocyte antigen (HLA) antibody specificities.

115 these cohorts to further fine map the human leukocyte antigen (HLA) association and replicated our r

116 )) and confirm the previously reported human leukocyte antigen (HLA) associations on chromosome 6p21

117 fied by several key examples and their human leukocyte antigen (HLA) associations: abacavir and HLA-B

118 ecurrence was higher for patients with human leukocyte antigen (HLA) B49 (odds ratio, 16.9; 95% confi

119 Efforts to precisely identify tumor human leukocyte antigen (HLA) bound peptides capable of mediat

120 namer and a decamer, all restricted by human leukocyte antigen (HLA) C*08:02.

121 Despite the progress in human leukocyte antigen (HLA) causal variant mapping, independ

122 The human leukocyte antigen (HLA) class I allele, HLA-C*06:02, is

123 While the relationship of protective human leukocyte antigen (HLA) class I alleles and HIV progress

124 the Middle East, sequenced HDV, typed human leukocyte antigen (HLA) class I alleles from patients, a

125 cy in epitopes presented by protective human leukocyte antigen (HLA) class I alleles.

126 Human leukocyte antigen (HLA) class I allotypes vary in their

127 Polymorphisms in the human leukocyte antigen (HLA) class I genes can cause the reje

128 ts with chronic HBV infection, and the human leukocyte antigen (HLA) class I genotype (A and B loci)

129 In all human cells, human leukocyte antigen (HLA) class I glycoproteins assemble w

130 lone's ability to downregulate CD4 and human leukocyte antigen (HLA) class I in vitro We then explore

131 Possession of the human leukocyte antigen (HLA) class I molecule B27 is strongly

132 or Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) Class I molecules bind to peptid

133 Micropolymorphisms within human leukocyte antigen (HLA) class I molecules can change the

134 Human leukocyte antigen (HLA) class I molecules generally pres

135 Peptides were eluted from human leukocyte antigen (HLA) class I molecules of MuV-infecte

136 me generates the epitopes presented on human leukocyte antigen (HLA) class I molecules that elicit CD

137 wo broad strategies for recognition of human leukocyte antigen (HLA) class I molecules: (i) direct re

138 ct the link between hyperexpression of human leukocyte antigen (HLA) class I on the islet cells, we e

139 Humanized mice expressing Human Leukocyte Antigen (HLA) class I or II transgenes have be

140 Human leukocyte antigen (HLA) class I-associated polymorphisms

141 ells, thus enabling their evasion from human leukocyte antigen (HLA) class I-restricted CD8(+) T-cell

142 c context influences HIV adaptation to human leukocyte antigen (HLA) class I-restricted immune pressu

143 e that allow it to escape detection by human leukocyte antigen (HLA) class I-restricted immune respon

144 ity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens i

145 n of dominant inhibitory receptors for human leukocyte antigen (HLA) class I.

146 eases pathogen resistance is linked to human leukocyte antigen (HLA) class I/II variants and their in

147 rexin), is so strongly associated with human leukocyte antigen (HLA) class II HLA-DQA1( *)01:02-DQB1(

148 ze peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II), whi

149 prediction of antigen presentation by human leukocyte antigen (HLA) class II molecules would be valu

150 Here, we demonstrate the presence of human leukocyte antigen (HLA) class II-restricted CD8(+) T cel

151 The immunoregulatory human leukocyte antigen (HLA) complex has been linked to susce

152 signal in the class III region of the human leukocyte antigen (HLA) complex in the South Asian datas

153 (MHC) protein which is encoded by the human leukocyte antigen (HLA) complex.

154 ein that are likely to be presented in human leukocyte antigen (HLA) complexes, and discuss the role

155 ransplant antibodies directed at donor human leukocyte antigen (HLA) donor-specific antibodies (DSA)

156 The development of human leukocyte antigen (HLA) donor-specific antibody/antibodi

157 Chemokine receptor 5 (CCR5), human leukocyte antigen (HLA) DR isotope, and cluster of diffe

158 with ABMR associated with de novo anti-human leukocyte antigen (HLA) DSA.

159 Human leukocyte antigen (HLA) gene variation is associated wit

160 Variation in the human leukocyte antigen (HLA) genes accounts for one-half of t

161 n thought to arise from alleles of the human leukocyte antigen (HLA) genes at that locus(3-6).

162 Human leukocyte antigen (HLA) genes confer substantial risk fo

163 equencing (NGS)-based typing of the 33 human leukocyte antigen (HLA) genes in 1,120 individuals of Ja

164 uencing studies have demonstrated that human leukocyte antigen (HLA) genes may be expressed in a cell

165 ymorphic genetic system in humans, the human leukocyte antigen (HLA) genes of the adaptive immune sys

166 ller immunoglobulin-like receptors and human leukocyte antigen (HLA) genotype with risk of CMV diseas

167 The human leukocyte antigen (HLA) haplotype reference panel used f

168 ght association of narcolepsy with the human leukocyte antigen (HLA) HLA-DQB1*06:02 allele, we first

169 DSA) directed against mismatched donor human leukocyte antigen (HLA) is a major risk factor for graft

170 ction between inhibitory receptors and human leukocyte antigen (HLA) ligands and bound peptide.

171 this locus, we imputed alleles at classical leukocyte antigen (HLA) loci using HLA*IMP:02 with a ref

172 plantation consider information at the human leukocyte antigen (HLA) loci.

173 However, loss of heterozygosity at the human leukocyte antigen (HLA) locus and loss of chromosome 8p

174 The human leukocyte antigen (HLA) locus is strongly associated wit

175 eral reports linked the disease to the human leukocyte antigen (HLA) locus on chromosome 6, followed

176 The human leukocyte antigen (HLA) locus plays a critical role in t

177 ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasi

178 e variation of survival with degree of human leukocyte antigen (HLA) mismatch.

179 Then, three decades ago, an unusual human leukocyte antigen (HLA) molecule was identified: HLA-G.

180 on the cell surface in the context of human leukocyte antigen (HLA) molecules have been targeted by

181 tors (KIRs) with their target ligands, human leukocyte antigen (HLA) molecules, is a critical compone

182 ct ASI to patients expressing specific Human Leukocyte Antigen (HLA) molecules, thus stratifying the

183 th high-affinity binding of autologous human leukocyte antigen (HLA) molecules.

184 uding the antigen-presenting classical human leukocyte antigen (HLA) molecules.

185 inding preferences of the best-matched Human Leukocyte Antigen (HLA) pocket for each SLA pocket.

186 increases the presentation of class I human leukocyte antigen (HLA) proteins that limit antiviral re

187 host, and is linked to their allele of human leukocyte antigen (HLA) proteins, which present protein

188 These include transcripts encoding human leukocyte antigen (HLA) receptors as well as B cell and

189 Fine-mapping of the human leukocyte antigen (HLA) region confirms the neurological

190 Genotype imputation of the human leukocyte antigen (HLA) region is a cost-effective means

191 Additionally, the human leukocyte antigen (HLA) region was comprehensively studi

192 n favoring sub-Saharan ancestry at the human leukocyte antigen (HLA) region, across North African ind

193 ancer associations were limited to the human leukocyte antigen (HLA) region, and classical HLA allele

194 tability of IQ might lie hidden in the human leukocyte antigen (HLA) region, which plays a critical r

195 ne, the C11orf30/LRRC32 locus, and the human leukocyte antigen (HLA) region.

196 nd imputation was used to fine-map the human leukocyte antigen (HLA) region.

197 ssociation studies and SNPs within the human leukocyte antigen (HLA) region.

198 Patterns of human leukocyte antigen (HLA) restriction of immunodominant ep

199 In addition, human leukocyte antigen (HLA) serotypes were also imputed.

200 suitability for HSCT is determined by Human Leukocyte Antigen (HLA) similarity.

201 Human leukocyte antigen (HLA) supertypes are groups of functio

202 Genes of the human leukocyte antigen (HLA) system encode cell-surface prote

203 high sequence divergence harboring the human leukocyte antigen (HLA) system, we found that local real

204 Moreover, using the human leukocyte antigen (HLA) transgenic rabbit model, we foun

205 purpose of this study was to identify human leukocyte antigen (HLA) type as risk and prognostic fact

206 ements a new graph alignment model for human leukocyte antigen (HLA) type inference, based on the pro

207 topes for each of the 6 most prevalent human leukocyte antigen (HLA) types.

208 kflow Language (CWL) implementation of human leukocyte antigen (HLA) typing using Polysolver or HLAmi

209 in vitro model of ABMR due to class I human leukocyte antigen (HLA) with and without complement acti

210 e peptides associated with the class I human leukocyte antigen (HLA), of which 98 peptides were deriv

211 Aggregate morphologies also influence Human Leukocyte Antigen (HLA)--types recognized by the aggrega

212 tients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 were trea

213 after immune-affinity purification of human leukocyte antigen (HLA)-A2 and bioinformatics to identif

214 e CD8(+) T cells in situ, in islets of human leukocyte antigen (HLA)-A2(+) donors and isolation and i

215 of genes encoding human cytokines and human leukocyte antigen (HLA)-A2.1 by adeno-associated virus s

216 ) (n) AAKKKYCL covalently bound to the human leukocyte antigen (HLA)-B*0801.

217 ariation of the two minimally distinct human leukocyte antigen (HLA)-B*27:05 and HLA-B*27:09 subtypes

218 Expression of human leukocyte antigen (HLA)-B27 is strongly associated with

219 Consecutive patients with AU who were human leukocyte antigen (HLA)-B27 positive or HLA-B27 negative

220 Identification of human leukocyte antigen (HLA)-bound peptides by liquid chromat

221 Human leukocyte antigen (HLA)-C*06:02 is identified as the all

222 udies suggest that the presence of the human leukocyte antigen (HLA)-Cw6 (C*06:02) allele may be a pr

223 The highly homologous human leukocyte antigen (HLA)-DQ2 molecules, HLA-DQ2.5 and HLA

224 Human leukocyte antigen (HLA)-DQ2.5 (DQA1*05/DQB1*02) is a cla

225 nd associations of narcolepsy with the human leukocyte antigen (HLA)-DQ6 allele and T-cell receptor a

226 eased expression of maturation markers human leukocyte antigen (HLA)-DR and CD86, enhanced tumor necr

227 d T-cell epitopes presented in vivo by human leukocyte antigen (HLA)-DR molecules in patients' inflam

228 ozygosity for the previously validated human leukocyte antigen (HLA)-DR*03:01 risk allele predicted i

229 We evaluated human leukocyte antigen (HLA)-DR/DQ molecular mismatch to pred

230 s have reported an association between human leukocyte antigen (HLA)-DRB1 and the risk of PD.

231 Specific alleles of the human leukocyte antigen (HLA)-DRB1 gene (HLA-DRB1) encode a "s

232 estricted by the human MHC-Ib molecule human leukocyte antigen (HLA)-E and specific for an epitope fr

233 The banking of human leukocyte antigen (HLA)-homozygous-induced pluripotent s

234 Human leukocyte antigen (HLA)-independent, T cell-mediated tar

235 et virus-derived peptides presented by human leukocyte antigen (HLA).

236 Antibodies targeting human leukocyte antigen (HLA)/major histocompatibility complex

237 inuclear antibodies (ANA), presence of human leukocyte antigen (HLA-)B27, age of onset of JIA, and se

238 gD, VP11/12, and VP13/14 proteins, in human leukocyte antigen (HLA-A*0201) transgenic rabbits infect

239 tributed to the genes encoding class I human leukocyte antigens (HLA) and the chemokine receptor CCR5

240 eterminants that underlie targeting of human leukocyte antigens (HLA) by anti-HLA alloantibodies is p

241 leles, genes or haplotypes) related to human leukocyte antigens (HLA), killer-cell immunoglobulin-lik

242 eveloped for other complex loci (e.g., human leukocyte antigen [HLA]) on the basis of SNP data provid

243 ed and mobilized within immunodominant human-leukocyte-antigen-(HLA)-A*11:01-restricted CD8(+) T cell

244 Understanding the binding between human leukocyte antigens (HLAs) and peptides is important to u

245 Interactions between human leukocyte antigens (HLAs) and peptides play a critical r

246 evasion of innate immunity.IMPORTANCE Human leukocyte antigens (HLAs) are cell surface proteins that

247 atibility complex (MHC), which encodes human leukocyte antigens (HLAs) in humans.

248 e peptides dissociate from the class I human leukocyte antigens (HLAs) upon acid denaturation.

249 harboring genes encoding the class II human leukocyte antigens (HLAs): rs557011[T] (minor allele fre

250 were simultaneously given marrow from a dog leukocyte antigen-identical donor.

251 similar epitopes presented by the same human leukocyte antigen II (HLA-II) molecule.

252 on a safe conversion to belatacept in human leukocyte antigen-immunized patients with low DSA levels

253 nversion from CNIs to belatacept in 29 human leukocyte antigen-immunized renal-transplant recipients.

254 SCCHN risk highlight the importance of human leukocyte antigen loci for oropharyngeal cancer risk, su

255 Genetic variation across the human leukocyte antigen loci is known to influence renal-trans

256 impact of genetic variation beyond the human leukocyte antigen loci is less clear.

257 iations to genetic variants, including human leukocyte antigen loci with carbamazepine-induced dermat

258 methylation of the region encoding the human leukocyte antigen locus (HLA).

259 ve tissue disorder associated with the human leukocyte antigen locus.

260 usceptibility has been associated with human leukocyte antigen locus.

261 , we present loss of heterozygosity in human leukocyte antigen (LOHHLA), a computational tool to dete

262 efined pre-transplant characteristics: human leukocyte antigen match (10/10 versus <10/10) and diseas

263 the recipient (younger donor or better human leukocyte antigen match), whereas delays beyond 3 months

264 ereas others may not have a compatible human leukocyte antigen-matched donor.

265 ere compared to CD4(+) responses in 10 human leukocyte antigen-matched persons with HCV spontaneous r

266 rted the first successful histocompatibility leukocyte antigen-matched sibling donor bone marrow and

267 n of hematopoietic stem cells from his human leukocyte antigen-matched sister 1 year prior to admissi

268 n of hematopoietic stem cells from his human leukocyte antigen-matched sister 1 year prior to admissi

269 sly and capable of recognizing cognate human leukocyte antigen-matched tumors are emerging as relevan

270 transplantation at age 49 with a 12/12 human leukocyte antigen-matched unrelated donor.

271 ty of performing combined histocompatibility leukocyte antigen-matched, sibling donor bone marrow and

272 Human leukocyte antigen mismatch number (hazards ratio, 1.35;

273 r T-cell-mediated rejection and BKVAN, human leukocyte antigen mismatch, cyclosporine therapy, and in

274 study, we extend those findings across a dog leukocyte antigen mismatched barrier.

275 o mixed lymphocyte co-cultures between human leukocyte antigen-mismatched peripheral blood lymphocyte

276 basiliximab induction, sex, donor age, human leukocyte antigen mismatches, human leukocyte antigen an

277 ow that both alleles of genes encoding human leukocyte antigen molecules and genes encoding component

278 with either loss of heterozygosity in human leukocyte antigens or depletion of expressed neoantigens

279 resented as peptides in the context of human leukocyte antigen (peptide-human leukocyte antigen compl

280 receptor (TCR) recognition of peptide-human leukocyte antigen (pHLA) complexes and is essential for

281 sed yeast-display libraries of peptide-human leukocyte antigen (pHLA) to screen for antigens of "orph

282 We tested the selectivity and efficacy of leukocyte antigen, PLAUR (plasminogen activator, urokina

283 Swine leukocyte antigens play indispensable roles in immune re

284 ivated C3 localized at synapses within human leukocyte antigen-positive cell processes and lysosomes,

285 olymorphism rs41269979 in the class II human leukocyte antigen region was more frequent in the invasi

286 nalysis to dissect associations in the human leukocyte antigen region, which suggests important roles

287 extracellular diffusible ligands or require leukocyte antigen-related (Lar), a receptor protein tyro

288 d, the receptor protein tyrosine phosphatase leukocyte-antigen-related (LAR), abolished activity rhyt

289 One such phosphatase, leukocyte-antigen-related (LAR), abolishes activity rhyt

290 gen receptor, enabling this simple non-human leukocyte antigen-restricted approach to enhanced CAR-T

291 characteristics, the identification of human leukocyte antigen risk alleles, and drug-induced prolife

292 ank of transplantation, and absence of human leukocyte antigen sensitization.

293 antibody cross-species reactivity with swine leukocyte antigen (SLA).

294 an knockout (KO) pig cells and class I swine leukocyte antigens (SLA).

295 ypes were detected among patients with human leukocyte antigen susceptibility alleles.

296 icroproteins that are presented by the human leukocyte antigen system.

297 and a highly multiplexed peptide-HLA (human leukocyte antigen) tetramer staining strategy, we probed

298 D (n = 10) patients, alongside genomic human leukocyte antigen typing.

299 n tumor antigen NY-ESO-1 (ESO) and the human leukocyte antigen variant HLA-A*0201 (A2) as a model and

300 creates a neoepitope presented by the human leukocyte antigen with the A2 serotype (HLA-A2) that has